Balkus Jennifer E, Manhart Lisa E, Lee Jeannette, Anzala Omu, Kimani Joshua, Schwebke Jane, Shafi Juma, Rivers Charles, Kabare Emanuel, Scott McClelland R
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Department of Global Health.
Department of Global Health Department of Epidemiology.
J Infect Dis. 2016 Jun 15;213(12):1932-7. doi: 10.1093/infdis/jiw043. Epub 2016 Feb 4.
Bacterial vaginosis (BV) may increase women's susceptibility to sexually transmitted infections (STIs). In a randomized trial of periodic presumptive treatment (PPT) to reduce vaginal infections, we observed a significant reduction in BV. We further assessed the intervention effect on incident Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium infection.
Nonpregnant, human immunodeficiency virus-uninfected women from the United States and Kenya received intravaginal metronidazole (750 mg) plus miconazole (200 mg) or placebo for 5 consecutive nights each month for 12 months. Genital fluid specimens were collected every other month. Poisson regression models were used to assess the intervention effect on STI acquisition.
Of 234 women enrolled, 221 had specimens available for analysis. Incidence of any bacterial STI (C. trachomatis, N. gonorrhoeae, or M. genitalium infection) was lower in the intervention arm, compared with the placebo arm (incidence rate ratio [IRR], 0.54; 95% confidence interval [CI], .32-.91). When assessed individually, reductions in STI incidences were similar but not statistically significant (IRRs, 0.50 [95% confidence interval {CI}, .20-1.23] for C. trachomatis infection, 0.56 [95% CI, .19-1.67] for N. gonorrhoeae infection, and 0.66 [95% CI, .38-1.15] for M. genitalium infection).
In addition to reducing BV, this PPT intervention may also reduce the risk of bacterial STI among women. Because BV is highly prevalent, often persists, and frequently recurs after treatment, interventions that reduce BV over extended periods could play a role in decreasing STI incidence globally.
细菌性阴道病(BV)可能会增加女性对性传播感染(STIs)的易感性。在一项旨在减少阴道感染的周期性推定治疗(PPT)随机试验中,我们观察到BV显著减少。我们进一步评估了该干预措施对沙眼衣原体、淋病奈瑟菌和生殖支原体感染发生率的影响。
来自美国和肯尼亚的未怀孕、未感染人类免疫缺陷病毒的女性,每月连续5晚接受阴道内甲硝唑(750毫克)加咪康唑(200毫克)或安慰剂治疗,为期12个月。每隔一个月收集生殖道液体标本。采用泊松回归模型评估干预措施对性传播感染获得的影响。
在234名登记的女性中,221名有可供分析的标本。与安慰剂组相比,干预组任何细菌性性传播感染(沙眼衣原体、淋病奈瑟菌或生殖支原体感染)的发生率较低(发病率比[IRR],0.54;95%置信区间[CI],0.32 - 0.91)。单独评估时,性传播感染发生率的降低情况相似但无统计学意义(沙眼衣原体感染的IRR为0.50[95%置信区间{CI},0.20 - 1.23],淋病奈瑟菌感染的IRR为0.56[95% CI,0.19 - 1.67],生殖支原体感染的IRR为0.66[95% CI,0.38 - 1.15])。
除了减少BV外,这种PPT干预措施还可能降低女性细菌性性传播感染的风险。由于BV非常普遍,经常持续存在,且治疗后频繁复发,长期减少BV的干预措施可能在全球范围内降低性传播感染的发生率方面发挥作用。